Beigene’s Global MAT2A Inhibitor Licensing Deal
BeiGene, soon to be BeOne Medicines, has secured global licensing rights for SYH2039, a novel MAT2A inhibitor, from CSPC....
Zelenectide Pevedotin Program Updates & Nectin-4 Gene Amplification Strategy
Bicycle Therapeutics presented data at the 2024 San Antonio Breast Conference Symposium (SABCS) highlighting the enhanced anti-tumor activity of...
Positive Results for Lunresertib & Camonsertib Combo in Gynecologic Trial
Repare Therapeutics announced positive data from its Phase 1 MYTHIC trial combining lunresertib and camonsertib (Lunre+Camo) in patients with...
Corcept Catalyst Trial Shows Positive Results in Cushing’s Syndrome & Diabetes Treatment
Corcept Therapeutics’ Phase 4 CATALYST study demonstrated that Korlym® significantly improved blood sugar control in patients with both Cushing’s...
Tobevibart & Elebsiran Get Breakthrough & PRIME for Chronic Hep D
Tobevibart and elebsiran, developed by Vir Biotechnology for chronic hepatitis delta (CHD), have received Breakthrough Therapy designation from the...
Atropos Evidence Network Automates Healthcare AI Model Training
Atropos Health launched AI model training on its Atropos Evidence Network, a federated healthcare data network containing over 300...
Stemline Therapeutics: New Therapeutic Strategy for Advanced Breast Cancer
Menarini Group, along with its subsidiary Stemline Therapeutics and research partner MEDSIR, presented research at the San Antonio Breast...
Corcept Announces Dazucorilant Phase 2 ALS Study Results
Corcept Therapeutics announced results from its Phase 2 DAZALS study of dazucorilant in patients with amyotrophic lateral sclerosis (ALS)....
Visugromab Reverses Checkpoint Inhibitor Resistance
CatalYm’s lead drug candidate, visugromab, a monoclonal antibody targeting the immunosuppressant GDF-15, has shown promising results in a Phase...
Spruce Biosciences Announces Topline Results from CAHmelia-204 and CAHptain-205 Trials
Spruce Biosciences announced topline results from two clinical trials, CAHmelia-204 and CAHptain-205, evaluating tildacerfont for congenital adrenal hyperplasia (CAH)....